Clinical Trial: Intranasal Stem Cells to Treat Perinatal Brain Injury to Combat Cerebral Palsy

U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07831746) titled 'Intranasal Stem Cells to Treat Perinatal Brain Injury to Combat Cerebral Palsy' on Sept. 11.

Brief Summary: Hypoxic-ischemic brain injury (HIBI) is a leading cause of death and lifelong disability in near-term and term infants, most often caused by perinatal arterial ischemic stroke (PAIS, incidence approximately 1:5000 live births) or perinatal asphyxia (PA, incidence 1-2:1000 live births). No treatment currently exists to repair or limit HIBI, and many affected infants go on to develop cerebral palsy, cognitive impairment, epilepsy, or visual or hearing deficits. Intranasally administered bone marrow-derived mesenchymal stromal c...